TNF-Inhibition with Etanercept for Graft-versus-Host Disease Prevention in High-Risk HCT: Lower TNFR1 Levels Correlate with Better Outcomes

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 10, 2012, Pages 1525-1532

  Choi, Sung W ^a   Stiff, Patrick ^b   Cooke, Kenneth ^c   Ferrara, James L M ^a   Braun, Thomas ^a   Kitko, Carrie ^a   Reddy, Pavan ^a   Yanik, Gregory ^a   Mineishi, Shin ^a   Paczesny, Sophie ^a   Hanauer, David ^a   Pawarode, Attaphol ^a   Peres, Edward ^a   Rodrigue, Tulio ^b   Smith, Scott ^b   Levine, John E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

GVHD; Hematopoietic cell transplantation; TNF ; TNFR1

Indexed keywords

ACICLOVIR; BUSULFAN; CARMUSTINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; ETANERCEPT; FLUDARABINE; LEVOFLOXACIN; METHOTREXATE; METHYLPREDNISOLONE; PALIFERMIN; PENTAMIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR RECEPTOR 1; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ARTICLE; BACTERIAL INFECTION; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INJECTION SITE HYPERSENSITIVITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; PROPHYLAXIS; SCHOOL CHILD; SURVIVAL; UNRELATED DONORS; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; WHOLE-BODY IRRADIATION;

EID: 84866144232     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.03.013     Document Type: Article

References (35)

1. Weisdorf D.J., Anasetti C., Antin J.H., et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002, 99:1971-1977.
2. Arora M., Weisdorf D.J., Spellman S.R., et al. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol 2009, 27:1644-1652.
3. Ciurea S.O., Saliba R.M., Rondon G., et al. Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 loci. Biol Blood Marrow Transplant 2011, 17:923-929.
4. Walter R.B., Pagel J.M., Gooley T.A., et al. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia 2010, 24:1276-1282.
5. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
6. Nash R., Piñeiro L., Storb R., et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood 1996, 88:3634-3641.
7. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
8. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 96:2062-2068.
9. Korngold R., Marini J.C., de Baca M.E., Murphy G.F., Giles-Komar J. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transplant 2003, 9:292-303.
10. Choi S.W., Kitko C.L., Braun T., et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 2008, 112:1539-1542.
11. Xun C.Q., Thompson J.S., Jennings C.D., Brown S.A., Widmer M.B. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994, 83:2360-2367.
12. Hill G.R., Teshima T., Rebel V.I., et al. The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity. J Immunol 2000, 164:656-663.
13. Korth-Bradley J.M., Rubin A.S., Hanna R.K., Simcoe D.K., Lebsack M.E. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000, 34:161-164.
14. Boeckh M., Huang M., Ferrenberg J., et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 2004, 42:1142-1148.
15. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1097.
16. Ascioglu S., Rex J.H., de Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002, 34:7-14.
17. Pzrepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
18. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
19. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
20. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
21. Hehlgans T., Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005, 115:1-20.
22. Jagasia M., Arora M., Flowers M.E., et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012, 119:296-307.
23. Hill G.R., Crawford J.M., Cooke K.R., Brinson Y.S., Pan L., Ferrara J.L. Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines. Blood 1997, 90:3204-3213.
24. van der Velden W.J., Herbers A.H., Feuth T., Schaap N.P., Donnelly J.P., Blijlevens N.M. Intestinal damage determines the inflammatory response and early complications in patients receiving conditioning for a stem cell transplantation. PLoS One 2010, 5:e15156.
25. Uberti J.P., Agovi M.A., Tarima S., et al. Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia. Bone Marrow Transplant 2011, 46:34-43.
26. Giles J.T., Bathon J.M. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 2004, 19:320-334.
27. Parody R., Martino R., Rovira M., et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant 2006, 12:734-748.
28. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010, 363:2091-2101.
29. Juvonen E., Aalto S., Tarkkanen J., Volin L., Hedman K., Ruutu T. Retrospective evaluation of serum Epstein Barr virus DNA levels in 406 allogeneic stem cell transplant patients. Haematologica 2007, 92:819-825.
30. Zerr D.M., Fann J.R., Breiger D., et al. HHV-6 reactivation and its effect on delirium and cognitive functioning in hematopoietic cell transplantation recipients. Blood 2011, 117:5243-5249.
31. Cornely O.A., Maertens J., Winston D.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356:348-359.
32. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356:335-347.
33. Wingard J.R., Carter S.L., Walsh T.J., et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010, 116:5111-5118.
34. Edinger M., Hoffmann P., Ermann J., et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003, 9:1144-1150.
35. Gatza E., Rogers C.E., Clouthier S.G., et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 2008, 112:1515-1521.